Neal D. Shore

Urology-specific quality measures are comingTwo electronic Clinical Quality Measures will help urologists report on prostate and bladder cancer care.
Congress says 'no' to Trump NIH budget cutsThe fiscal 2017 appropriations wrap-up package approved by Congress in early May included a $2 billion increase for the National Institutes of Health, despite a Trump administration request for a $1.2 billion reduction for the nation’s primary medical research facility. That bipartisan action, which funds the federal government through September, came in the face of President Trump’s demand to slash spending for domestic programs to pay for a huge increase in appropriations for defense.
Off the fee-for-service hamster wheel
Prostate cancer guidelines: A primer for urologistsFour current clinical practice guidelines on prostate cancer provide urologists with valuable, evidence-based decision points about diagnosis and treatment while raising questions that will likely be addressed by future research.
Concomitant Ra 223, abiraterone found safe, effectiveRadium 223 dichloride (Ra 223 [Xofigo]) can be safely combined with abiraterone acetate (ZYTIGA) for the treatment of patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases, and appears to result in decreased bone pain and improved quality of life, according to the interim results of an open-label prospective study known as eRADicAte.
What’s on your colleagues’ wish lists for 2016We asked members of our editorial board what they hope to see in the world of urology in the coming year.
Oral antiandrogen safe, well tolerated in phase II trial
Oral antiandrogen safe, well tolerated in phase II trialARN-509, a novel oral antiandrogen, was safe, well tolerated, and showed promising efficacy in men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC) in a phase II study, reported Neal D. Shore, MD.
LUGPA extends its reach to urology practices large and smallIn his latest blog post, urologist Neal D. Shore, MD, discusses LUGPA's recent expansion to include independent practices of five or more physicians.
Approval of enzalutamide pre-chemo a ‘game changer’
Approval of enzalutamide pre-chemo a ‘game changer’The FDA’s approval of enzalutamide (XTANDI) to treat metastatic castration-resistant prostate cancer (CRPC) in the pre-chemotherapy setting is a potential game changer for both patients and treating physicians, especially urologists, according to leaders in the prostate cancer field.
Upfront chemo: Time to take noticeThe “embarrassment of riches” of therapeutic options for advanced prostate cancer fortunately continues, encouraging us all to strive for lessening the incidence and impact of prostate cancer-specific mortality.